Novo Nordisk’s head start on GLP-1 pills forces investors to rethink Eli Lilly's dominance

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.

This page shows a summary and AI analysis only. For the full original article, use the “Read Original” button above.